Aug 15, 2019
Ovarian Cancer Diagnostics Market Size Worth $2 Billion By 2026: Grand View Research, Inc.
Jun 01, 2018
Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting
Feb 12, 2018
OncoQuest to Present at BIO CEO & Investor Conference
Feb 06, 2018
OncoQuest Completes US$6 Million Private Placement
Dec 11, 2017
Morphotek And Rockefeller University Form A Sponsored Research Agreement To Study The Immunosuppressive Effects Of The Tumor Shed Antigen CA125 And Its Potential Impact In Future Patient Therapies
Nov 16, 2017
Vermillion Announces Publication of Foundational Health Economics Study
Nov 14, 2017
OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)
Nov 02, 2017
OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting
Nov 01, 2017
ASPiRA Labs Announces a Major Coverage Milestone - A 27% Increase in Covered Lives for OVA1
Oct 31, 2017
ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield
Oct 02, 2017
ASPiRA Labs Announces In-Network Contract Agreement with HealthNet Federal Services for OVA1®
Sep 05, 2017
Morphotek®, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®
Aug 31, 2017
Vermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell
Jul 26, 2017
First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer